Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Top Cited Papers
- 8 April 2021
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 384 (14), 1289-1300
- https://doi.org/10.1056/nejmoa2035716
Abstract
Lenvatinib in combination with pembrolizumab or everolimus has activity against advanced renal cell carcinoma. The efficacy of these regimens as compared with that of sunitinib is unclear.Keywords
Funding Information
- Eisai Inc.
- merck sharp & dohme corp., a subsidiary of merck & co., inc.
This publication has 19 references indexed in Scilit:
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell CarcinomaThe New England Journal of Medicine, 2019
- Evolving Systemic Treatment Landscape for Patients With Advanced Renal Cell CarcinomaJournal of Clinical Oncology, 2018
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell CarcinomaThe New England Journal of Medicine, 2018
- Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN TrialJournal of Clinical Oncology, 2017
- Systemic Therapy for Metastatic Renal-Cell CarcinomaThe New England Journal of Medicine, 2017
- Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trialThe Lancet Oncology, 2015
- A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)Cancer Chemotherapy and Pharmacology, 2013
- Multiple Testing in Group Sequential Trials Using Graphical ApproachesStatistics in Biopharmaceutical Research, 2013
- Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell CarcinomaJournal of Clinical Oncology, 2002
- Karnofsky performance status revisited: reliability, validity, and guidelines.Journal of Clinical Oncology, 1984